Overview
PNC-27 is a chimeric peptide: a segment of the p53 protein that binds HDM-2 (the human homologue of MDM2), fused to penetratin, a cell-penetrating sequence.
Its proposed mechanism is unusual and worth stating precisely, because it is often described loosely. PNC-27 does not restore p53 tumour-suppressor signalling. It is reported to bind HDM-2 that is expressed
in the plasma membrane of cancer cells, and to form transmembrane pores, killing the cell by
necrosis rather than apoptosis. In the closely related PNC-28, treatment produced rapid lactate dehydrogenase release without elevation of the pro-apoptotic proteins seen in p53-induced apoptosis — the signature of membrane lysis, not programmed cell death.
The penetratin sequence turned out to be responsible for that distinction. When the same p53 segment was expressed inside cells by plasmid transfection, without penetratin, the cells died by apoptosis instead — high caspase-3 and -7 and annexin V, background LDH. The fusion partner does not merely deliver the peptide; it changes the mechanism of killing.
Selectivity is claimed to follow from membrane HDM-2 expression. In ovarian cancer lines SKOV-3 and OVCAR-3, HDM-2 was highly expressed in the plasma membrane and PNC-27 colocalised with it, producing rapid necrosis; in non-transformed HUVEC control cells with minimal membrane HDM-2, there was no colocalisation and no cytotoxicity.
This work spans roughly two decades and multiple tumour types, but remains preclinical. No published human clinical trial was located.
What the evidence shows
Separated by study type- HumanClinical trials and human studies
- No published human clinical trials located.
- AnimalRodent and other animal models
- Preclinical work spans multiple solid tumour and haematologic malignancy models.
- In vitroCell and tissue studies
- Colocalised with membrane HDM-2 in SKOV-3 and OVCAR-3 ovarian cancer lines producing rapid necrosis, with no colocalisation or cytotoxicity in non-transformed HUVEC cells expressing minimal membrane HDM-2. The related PNC-28 caused rapid LDH release and membrane pore formation in MiaPaCa-2 pancreatic cancer cells without elevation of pro-apoptotic proteins.
Key studies & findings
2 studies- 1
HDM-2 was highly expressed in the plasma membranes of SKOV-3 and OVCAR-3 ovarian cancer cells and PNC-27 colocalised with it, causing rapid necrosis; non-transformed HUVEC cells with minimal membrane HDM-2 showed no colocalisation and no cytotoxicity.
- 2
The penetratin sequence — not the p53 segment alone — determines the killing mechanism: penetratin-fused peptide caused necrosis via membrane pore formation, whereas the same p53 segment expressed intracellularly by transfection caused apoptosis with high caspase-3/7 and annexin V.
Benefits & effects
3 documentedSelective necrosis of cancer cell lines expressing membrane HDM-2
No cytotoxicity toward non-transformed HUVEC controls
Activity documented across multiple solid tumour and haematologic models
Side effects & safety
2 reportedSafety noteResearch compound for laboratory use only. Not approved for human use; no established human safety database outside the trials cited here.
Recorded in the cited literature No human safety data published.
Pore-forming mechanism is intrinsically non-selective at the chemistry level
Selectivity depends entirely on differential membrane HDM-2 expression
Limitations & open questions
Despite roughly two decades of publication, PNC-27 has not entered published human trials, and much of the literature comes from a small group of collaborating investigators. A membrane-pore-forming mechanism is inherently non-specific at the chemistry level — selectivity depends entirely on the claim that non-cancerous cells display little membrane HDM-2, which is a narrower safety margin than a receptor-mediated mechanism would provide. This is an oncology research compound; using it outside a laboratory setting has no evidential basis whatsoever.
Pharmacology
PNC-27 is a large chimeric peptide (C188H293N53O44S, MW approximately 4032, CAS 1159861-00-3, PubChem CID 16201774) comprising a p53 HDM-2-binding segment fused to the penetratin cell-penetrating sequence. No human pharmacokinetic data exist.
Frequently asked questions
Does PNC-27 restore p53 function?
No. That is a common misreading. It uses a p53-derived sequence to bind HDM-2 in the cancer cell membrane and form pores, killing by necrosis. It does not restore p53 tumour-suppressor signalling inside the cell.
Why does the penetratin part matter so much?
It changes the mechanism, not just the delivery. With penetratin, cells died by necrosis with membrane pore formation and LDH release. The same p53 segment expressed inside cells without penetratin killed by apoptosis instead.
What makes it selective for cancer cells?
The claim is that transformed cells express HDM-2 in their plasma membrane while normal cells largely do not. In the ovarian cancer study, PNC-27 colocalised with membrane HDM-2 in cancer lines but not in non-transformed HUVEC cells, which were not killed.
Is PNC-27 a cancer treatment?
No. It is a preclinical research compound with no published human trials. Nothing here should be read as a treatment option.
Citations
2 sources- 1Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes
- 2